Stoke TherapeuticsSTOK
Recorded

Stoke Therapeutics Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration25 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Andrew TsaiSenior Biotech Analyst

Okay. We're going to get started. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies, and it's my pleasure to have the Stoke team with me. To my direct left is Ian Smith, CEO, and to his left, Jason Hoitt, Chief Patient Officer. Welcome, both of you. Thank you, Andrew.

Andrew TsaiSenior Biotech Analyst

Maybe to begin, can you please discuss your pipeline, the Stoke story, your lead program, and milestones over the next six to 12 months? That would be helpful. Yeah.

Ian SmithCEO

Thank you, Andrew, and thank you for those that are joining us both on the webcast and here in person today. Stoke Therapeutics is a company that focuses on genetic medicines and genetic diseases. Our primary focus at this point is a medicine for Dravet syndrome. Dravet syndrome is a genetic epilepsy, and we have a medicine that goes to the root cause of the disease and addresses a protein that is not expressed in the sufficient levels, and we upregulate that protein to go to the root cause of the disease and potentially provide clinical benefit with our medicine, zorevunersen. That medicine is in phase III study that I'm sure we'll talk to.

Ian SmithCEO

Yeah Today, Andrew. Beyond zorevunersen, we also have a next medicine.

Ian SmithCEO

It is an autosomal dominant optic atrophy, which is a genetic progressive loss of eyesight, where patients with ADOA also move, unfortunately, to being legally blind. Our hope with that medicine is actually to restore vision. Not just to stabilize vision, but potentially restore vision for those children and older adults, younger adults who have actually lost their vision. It is a very similar approach to the Dravet approach, where we upregulate a protein that is insufficient in these patients. Given the success we have had in Dravet, we anticipate that the same approach in ADOA may result clinical benefits and may restore vision for these patients. We also have a number of other earlier stage efforts based on mainly haploinsufficient diseases.

Ian SmithCEO

What that means is they do express protein, but you do not express the protein to the level that they need to be a healthy child, mainly. We hope to address those as well. They are primarily in the neuroscience area or neurology area, and I look forward to talking to you about those in the future.

Ian SmithCEO

We just came off our third quarter conference call about two weeks ago, where we updated the investment community on our progress with our phase III study. I look forward to doing that today and taking all your questions. Once again, I thank you for joining us today.

Andrew TsaiSenior Biotech Analyst

Great. Maybe to start, to level set the market opportunity for zorevunersen data, phase III data, pivotal data, third quarter of next year. Existing drugs for epilepsy reduce seizures, obviously, but none of them benefit neurodevelopmental cognition. Your drug seems to do that. Maybe first, can you speak to what that means in terms of pricing power? How much could that price be if you did show cognitive benefits?

Ian SmithCEO

That's a complex question, Andrew, because I would say it's not. When you ask the question as in, "Can you help us understand the pricing power if we show cognitive benefits?" I would posit that we've already shown cognitive benefits.

Ian SmithCEO

This answer deserves a little unpacking of what I mean by that. We've studied zorevunersen in a phase I/II study and over into an open-label study. The patients that were in the phase I/II, 90% of those patients chose to roll over into an OLE study, and we've been able to study those patients for a further four years after the phase I/II study. Studying those patients for four years, what we see in the data is a continued reduction in seizures. At the doses that are more consistent with the phase III dosing, we see seizure reductions of 80%, 85%. That itself is very important in terms of what this medicine benefit may provide to the patient. What it also allowed us to do is to study the cognition and behavioral benefits over a four-year period.

Ian SmithCEO

That data has, each year, over many domains of what's called Vineland-3, has been able to show that we've improved receptive communication, expressive communication, personal behaviors or personal interactions, and also interpersonal skills. All of that data has been collected from a body of patients ranging between 60 and 70, 75 patients, I believe it is, over a period of four years. All of that data has actually been taken together, both the seizures and the OLE data, the cognition and behavioral data from the OLE, and actually shared with a payer. We've done a lot of research as well, and I'm going to ask Jason to comment on that in a moment.

Ian SmithCEO

The payer looks at this in terms of the totality of the data, not just as in, do you need to hit your end point in the phase III, 52-week phase III study. We already believe that we've shown that with this total body of data, that this medicine, because it goes to the root cause of the disease, there's a plausible mechanistic pathway in terms of addressing NaV1.1, the protein that needs to be expressed, that this medicine has both seizure reduction benefits as well as cognition and behavioral benefits. That's the position on the value of our medicine. I don't know whether you want to add, Jason.

Jason HoittChief Patient Officer

Yeah, I would just say that, when you think about promoting a drug like zorevunersen, obviously you're tied to what's specifically written in your label. But I think when payers are evaluating coverage policy for a medicine like zorevunersen, they're going to look at the totality of the evidence, right? I think the label is one piece of that, but they're also going to look at the published literature, what's in the public domain in terms of peer-reviewed presentations at scientific meetings, and look at holistically what this means.

Jason HoittChief Patient Officer

When we put different scenarios in front of payers and say, "What will be the most important piece of evidence to you as you think about writing a medical policy on the other side of phase III data and approval?" They say the long-term open-label extension data is more compelling from their perspective than a 52-week endpoint, because they're thinking about a chronic lifelong treatment for that patient and what it's going to mean from a safety and efficacy perspective over the long haul.

Andrew TsaiSenior Biotech Analyst

Mm-hmm. What does that mean for price?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day